Emerging Trends in T-cell based Vaccines

Since Edward Jenner’s first use of cowpox pustules against smallpox to the present use of subunit vaccines, vaccinology has seen a paradigm shift. The transition from time-intensive microbiological approaches to the current machine learningbased prediction algorithms for epitope identification have enabled the development of faster, cost-effective and efficient vaccines. However, to outrace the newer and deadlier emerging pathogens, our approach to vaccination needs to be constantly modified. As we mark the final year of the Decade of Vaccines and its product Global Vaccine Action Plan (GVAP), we emphasize the significance of Tcell responses to achieve a successful vaccination. While the traditional vaccination approaches mostly relied on antibody generation as a measure of vaccine efficacy; recent years have seen a rekindled interest in T-cells’ role for immunoprotection. In fact, current vaccination approaches against a number of pathogens are exclusively designed to elicit Tcell-based immune response. Such an approach is particularly useful in persistent latestage chronic viral infections, where the body is unable to clear the infection (such as human immunodeficiency virus (HIV) [1], hepatitis C virus (HCV) [2], cytomegalovirus (CMV) [3], vaccinia virus [4]). Moreover, T-cell responses show a greater magnitude, affinity, and multifunctionality which can be tailored against the invading pathogens. In addition to its obvious advantage in chronic viral infections, Tcell-based immunity is widely used against intracellular bacteria [5] and is also currently being targeted in cancer [6], autoimmune disorders [7], allergies [8], and even fibrosis [9].


Opinion
Since Edward Jenner's first use of cowpox pustules against smallpox to the present use of subunit vaccines, vaccinology has seen a paradigm shift. The transition from time-intensive microbiological approaches to the current machine learningbased prediction algorithms for epitope identification have enabled the development of faster, cost-effective and efficient vaccines. However, to outrace the newer and deadlier emerging pathogens, our approach to vaccination needs to be constantly  [2], cytomegalovirus (CMV) [3], vaccinia virus [4]). Moreover, T-cell responses show a greater magnitude, affinity, and multifunctionality which can be tailored against the invading pathogens. In addition to its obvious advantage in chronic viral infections, T-cell-based immunity is widely used against intracellular bacteria [5] and is also currently being targeted in cancer [6], autoimmune disorders [7], allergies [8], and even fibrosis [9].
The success of any vaccination depends on the identification of effective epitopes, which is greatly expedited by the use of computational tools (referred to as immunoinformatics). For T-cell epitope mapping, two distinct approaches exist. In an epitope-based approach, top-most antigenic epitopes are selected by screening a subset of proteins or the entire proteome of an organism. Such an approach eliminates non-immunogenic sequences and is therefore expected to elicit a robust immune response [10]. Overlapping peptides uses a library of promiscuous peptides to stimulate T-cell responses without knowledge of the epitopes or individual's genetic makeup [11]. In contrast to antibody response, antigen recognition by both and are currently being developed for HCV [13], measles [14] and several cancers [15]. Moreover, understanding of the association between an individual's genetic makeup and immune response to the administered vaccines is important to predict the success of immunization where HLA polymorphism is known to confer a variability in immune response (E.g., the adverse reaction in case of vaccinia virus [16]). Such an approach can also be adopted adverse event. Recently, we have identified peptides against all 12 superfamilies of HLAI and 27 reference alleles of HLAII, which can be used in developing HLA specific personalized vaccine in BK viremia [17]. Thus, the beauty of T-cell based vaccine is that while on one hand it can be designed to achieve a personalized response (using specific HLA epitopes), it can be also be developed as a universal vaccine (using epitopes that can bind to all major HLA molecules). measures T-cell diversity upon vaccination [19]. Before proceeding to the clinical trials, studies in animal models provide information on vaccine safety, efficacy, optimal dose, formulation and route of delivery. While mice are the most common species for vaccine research, the similarity in disease pathogenesis dictates rabbits as the primary experimental models a number of human infections [20]. Overall, animals show a higher immune response than humans (which also show a variable response due to genetic polymorphism).
Peptides are delivered either as a DNA vaccine in viral vectors (most commonly adenovirus) or as a vaccine cocktail [21,22].
To enhance their immunogenicity epitope-based vaccines also require the use of adjuvants. There is not much research on T-cellspecific adjuvant development. The most common adjuvants are pathogen-associated molecular pattern (PAMP) based, which can be added in the vaccine cocktail or molecularly linked to the vaccine constructs [23]. Viral vectors also improve the immunogenicity of the immunodominant epitopes in vivo [21]. Another challenge to T-cell-based vaccination is the lack of long-term memory T-cell formation with antigens requiring repeated vaccination [21,24].
Future research in this direction also requires the development of adjuvants that can generate specific Th responses (Th1or Th17).
Targeting the T-cell inhibitory molecules like PD-1 and CTLA-4 or T-cell metabolism can maximize T-cell activation and are currently being utilized [24].
Vaccines are the single-most-important factor in eradicating a number of infectious diseases and greatly reducing the prevalence of many more. We have come a long way since the empirical approach to vaccination, to a much better understanding of how the specific vaccine components activate the immune system. However, despite significant technological and biological advancements, the generation of vaccine-based immunoprotection still remains a challenge for many existing diseases. Moreover, newly emerging deadly pathogens of epidemic potential-such as Zika, Ebola, Coronavirus -will continue to fuel our constant war against microbial pathogens.